- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
LONDON, Feb. 11, 2021 /PRNewswire/ BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI s scientific and technical expertise now entering human clinical trials.
BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients with mild to moderate disease.
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
-
AI-generated target was identified through The Benevolent Platform and AstraZeneca s scientific expertise and rich datasets
LONDON, Jan. 27, 2021 /PRNewswire/ BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company s portfolio. The Benevolent Platform predicted this novel target, which was subsequently biologically validated through AstraZeneca s rigorous experimental testing.
In 2019, BenevolentAI and AstraZeneca entered a strategic collaboration aiming to discover new drugs for CKD and idiopathic pulmonary fibrosis (IPF). The partnership combines AstraZeneca s scientific expertise and rich datasets with BenevolentAI s target identification platform and biom